ii. For Stöckert 3T HCDs that have been manufactured AFTER September 2014 and all other HCDs, follow the recommendations detailed in Sections 1-5. The additional risk posed by this issue has been reported as between 1 in 100 and 1 in 1000 patients, with cases identified to date predominantly being associated with valve replacement or repair. The decision to use a contaminated device should be made in conjunction with clinicians undertaking the proposed surgical procedures and an infection control team. For all devices, ensure that the risk of infection is communicated to patients as part of the consent process. State or territory government contacts If you require further information or advice on issues related to HCDs please contact your state or territory government contact listed below. State / Territory State or Territory Contact Peter Collignon, ACT Health ACT Pathology ACT P: 02 6244 2891 E: Paul Curtis, Clinical Excellence Commission Clinical Governance NSW P: 02 9269 5569 E: Kirstine Sketcher-Baker, Queensland Health Patient Safety Unit QLD P: 07 3328 9424 E: Irene Wilkinson, SA Health Communicable Disease Control Branch SA P: 08 7425 7170 E: Annie Wells, Department of Health and Human Services Public Health Services TAS P: 03 6166 0605 E: Jonathan Prescott, Department of Health and Human Services Safety Programs VIC P: 03 9096 7258 E. Paul Armstrong, WA Health Department of Public Health, Communicable Disease Control Directorate WA P: 08 9388 4800 E: resources available Therapeutics Goods Administration Alert, dated 28 October 2016: Alert, dated 2 August 2016: Medical Devices Safety Update, dated 2 May 2016: Public Health Laboratory Network
ii. For Stöckert 3T HCDs that have been manufactured AFTER September 2014 and all other HCDs, follow the recommendations detailed in Sections 1-5. The additional risk posed by this issue has been reported as between 1 in 100 and 1 in 1000 patients, with cases identified to date predominantly being associated with valve replacement or repair. The decision to use a contaminated device should be made in conjunction with clinicians undertaking the proposed surgical procedures and an infection control team. For all devices, ensure that the risk of infection is communicated to patients as part of the consent process. State or territory government contacts If you require further information or advice on issues related to HCDs please contact your state or territory government contact listed below. State / Territory State or Territory Contact ACT Peter Collignon, ACT Health ACT Pathology P: 02 6244 2891 E: NSW Paul Curtis, Clinical Excellence Commission Clinical Governance P: 02 9269 5569 E: QLD Kirstine Sketcher-Baker, Queensland Health Patient Safety Unit P: 07 3328 9424 E: SA Irene Wilkinson, SA Health Communicable Disease Control Branch P: 08 7425 7170 E: TAS Annie Wells, Department of Health and Human Services Public Health Services P: 03 6166 0605 E: VIC Jonathan Prescott, Department of Health and Human Services Safety Programs P: 03 9096 7258 E. WA Paul Armstrong, WA Health Department of Public Health, Communicable Disease Control Directorate P: 08 9388 4800 E: resources available Therapeutics Goods Administration Alert, dated 28 October 2016: Alert, dated 2 August 2016: Medical Devices Safety Update, dated 2 May 2016: Public Health Laboratory Network
National-Infection-Control-Guidance.docx